This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
Newsramp
newsramp.com
did:plc:xlsujlrwr5xpfxgaf4pixhri
Soligenix reports no safety concerns in Phase 3 FLASH2 trial for HyBryte, advancing treatment options for early-stage cutaneous T-cell lymphoma. Promising progress in rare disease therapeutics. #Biotech #RareDiseases
2025-11-25T18:44:06.430Z